Consolidated Statements of Stockholders' Equity (Deficit) - USD ($) $ in Thousands	Ironwood Pharmaceuticals, Inc. stockholders' equity (deficit) Cumulative Effect, Period of Adoption, Adjustment	Ironwood Pharmaceuticals, Inc. stockholders' equity (deficit)	Common Stock	Additional paid-in capital Cumulative Effect, Period of Adoption, Adjustment	Additional paid-in capital	Accumulated deficit Cumulative Effect, Period of Adoption, Adjustment	Accumulated deficit	Accumulated other comprehensive loss	Noncontrolling Interest	Cumulative Effect, Period of Adoption, Adjustment	Total
Balance at Dec. 31, 2021	$ (44,050)	$ 605,911	$ 162	$ (110,217)	$ 1,543,357	$ 66,167	$ (937,608)			$ (44,050)	$ 605,911
Balance (in shares) at Dec. 31, 2021			162,036,461
Increase (Decrease) in Stockholders' Equity (Deficit)
Issuance of common stock related to share-based awards and employee stock purchase plan		11,790	$ 3		11,787						11,790
Issuance of common stock related to share-based awards and employee stock purchase plan (in shares)			2,756,841
Share-based compensation expense related to share-based awards and employee stock purchase plan		27,048			27,048						27,048
Repurchases of common stock		(123,386)	$ (11)		(123,375)						$ (123,386)
Repurchases of common stock (in shares)			(10,766,353)								(10,800,000)
Net income (loss)		175,065					175,065				$ 175,065
Balance at Dec. 31, 2022		652,378	$ 154		1,348,600		(696,376)				652,378
Balance (in shares) at Dec. 31, 2022			154,026,949
Increase (Decrease) in Stockholders' Equity (Deficit)
Issuance of common stock related to share-based awards and employee stock purchase plan		4,005	$ 2		4,003						4,005
Issuance of common stock related to share-based awards and employee stock purchase plan (in shares)			2,327,289
Share-based compensation expense related to share-based awards and employee stock purchase plan		32,005			32,005						32,005
Noncontrolling interests on acquisition of VectivBio Holding AG									$ 26,218		26,218
Purchase of subsidiary shares from noncontrolling interests		(29,476)			(29,413)			$ (63)	3,165		(26,311)
Net income (loss)		(1,002,239)					(1,002,239)		(29,320)		(1,031,559)
Other comprehensive income (loss), net of tax		(2,968)						(2,968)	$ (63)		(3,031)
Balance at Dec. 31, 2023		(346,295)	$ 156		1,355,195		(1,698,615)	(3,031)			$ (346,295)
Balance (in shares) at Dec. 31, 2023			156,354,238								156,354,238
Increase (Decrease) in Stockholders' Equity (Deficit)
Issuance of common stock related to share-based awards and employee stock purchase plan		11,013	$ 4		11,009						$ 11,013
Issuance of common stock related to share-based awards and employee stock purchase plan (in shares)			3,851,661
Share-based compensation expense related to share-based awards and employee stock purchase plan		29,850			29,850						29,850
Taxes paid related to net share settlement of share-based awards		(737)			(737)						(737)
Net income (loss)		880					880				880
Other comprehensive income (loss), net of tax		3,954						3,954			3,954
Balance at Dec. 31, 2024		$ (301,335)	$ 160		$ 1,395,317		$ (1,697,735)	$ 923			$ (301,335)
Balance (in shares) at Dec. 31, 2024			160,205,899								160,205,899